These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
138 related articles for article (PubMed ID: 20452347)
1. Dyskinetic potential of dopamine agonists is associated with different striatonigral/striatopallidal zif-268 expression. Carta AR; Frau L; Pinna A; Morelli M Exp Neurol; 2010 Aug; 224(2):395-402. PubMed ID: 20452347 [TBL] [Abstract][Full Text] [Related]
2. Behavioral and biochemical correlates of the dyskinetic potential of dopaminergic agonists in the 6-OHDA lesioned rat. Carta AR; Frau L; Pinna A; Pontis S; Simola N; Schintu N; Morelli M Synapse; 2008 Jul; 62(7):524-33. PubMed ID: 18435422 [TBL] [Abstract][Full Text] [Related]
3. Different responsiveness of striatonigral and striatopallidal neurons to L-DOPA after a subchronic intermittent L-DOPA treatment. Carta AR; Tronci E; Pinna A; Morelli M Eur J Neurosci; 2005 Mar; 21(5):1196-204. PubMed ID: 15813929 [TBL] [Abstract][Full Text] [Related]
4. Performance of movement in hemiparkinsonian rats influences the modifications induced by dopamine agonists in striatal efferent dynorphinergic neurons. Frau L; Morelli M; Simola N Exp Neurol; 2013 Sep; 247():663-72. PubMed ID: 23499830 [TBL] [Abstract][Full Text] [Related]
5. Direct and indirect striatal efferent pathways are differentially influenced by low and high dyskinetic drugs: behavioural and biochemical evidence. Carta AR; Frau L; Pontis S; Pinna A; Morelli M Parkinsonism Relat Disord; 2008; 14 Suppl 2():S165-8. PubMed ID: 18583175 [TBL] [Abstract][Full Text] [Related]
6. D1 and D2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons. Gerfen CR; Engber TM; Mahan LC; Susel Z; Chase TN; Monsma FJ; Sibley DR Science; 1990 Dec; 250(4986):1429-32. PubMed ID: 2147780 [TBL] [Abstract][Full Text] [Related]
7. Electrophysiological effects of SKF 38393 in rats with reserpine treatment and 6-hydroxydopamine-induced nigrostriatal lesions reveal two types of plasticity in D1 dopamine receptor modulation of basal ganglia output. Huang KX; Walters JR J Pharmacol Exp Ther; 1994 Dec; 271(3):1434-43. PubMed ID: 7996456 [TBL] [Abstract][Full Text] [Related]
8. The full D1 dopamine receptor agonist SKF-82958 induces neuropeptide mRNA in the normosensitive striatum of rats: regulation of D1/D2 interactions by muscarinic receptors. Wang JQ; McGinty JF J Pharmacol Exp Ther; 1997 May; 281(2):972-82. PubMed ID: 9152408 [TBL] [Abstract][Full Text] [Related]
9. Nigrostriatal lesion and dopamine agonists affect firing patterns of rodent entopeduncular nucleus neurons. Ruskin DN; Bergstrom DA; Walters JR J Neurophysiol; 2002 Jul; 88(1):487-96. PubMed ID: 12091570 [TBL] [Abstract][Full Text] [Related]
10. Effects of full D1 dopamine receptor agonists on firing rates in the globus pallidus and substantia nigra pars compacta in vivo: tests for D1 receptor selectivity and comparisons to the partial agonist SKF 38393. Ruskin DN; Rawji SS; Walters JR J Pharmacol Exp Ther; 1998 Jul; 286(1):272-81. PubMed ID: 9655869 [TBL] [Abstract][Full Text] [Related]
11. Selective modifications in GAD67 mRNA levels in striatonigral and striatopallidal pathways correlate to dopamine agonist priming in 6-hydroxydopamine-lesioned rats. Carta AR; Fenu S; Pala P; Tronci E; Morelli M Eur J Neurosci; 2003 Nov; 18(9):2563-72. PubMed ID: 14622157 [TBL] [Abstract][Full Text] [Related]
12. D1 and D2 dopamine receptors differentially regulate c-fos expression in striatonigral and striatopallidal neurons. Robertson GS; Vincent SR; Fibiger HC Neuroscience; 1992 Jul; 49(2):285-96. PubMed ID: 1359451 [TBL] [Abstract][Full Text] [Related]
13. Repeated D1 dopamine receptor agonist administration prevents the development of both D1 and D2 striatal receptor supersensitivity following denervation. Hu XT; White FJ Synapse; 1992 Mar; 10(3):206-16. PubMed ID: 1532677 [TBL] [Abstract][Full Text] [Related]
15. D2 receptor stimulation, but not D1, restores striatal equilibrium in a rat model of Parkinsonism. Ballion B; Frenois F; Zold CL; Chetrit J; Murer MG; Gonon F Neurobiol Dis; 2009 Sep; 35(3):376-84. PubMed ID: 19501163 [TBL] [Abstract][Full Text] [Related]
17. Potentiation of amphetamine-mediated responses in caffeine-sensitized rats involves modifications in A2A receptors and zif-268 mRNAs in striatal neurons. Tronci E; Simola N; Carta AR; De Luca MA; Morelli M J Neurochem; 2006 Aug; 98(4):1078-89. PubMed ID: 16771831 [TBL] [Abstract][Full Text] [Related]
18. L-DOPA-induced dopamine efflux in the striatum and the substantia nigra in a rat model of Parkinson's disease: temporal and quantitative relationship to the expression of dyskinesia. Lindgren HS; Andersson DR; Lagerkvist S; Nissbrandt H; Cenci MA J Neurochem; 2010 Mar; 112(6):1465-76. PubMed ID: 20050978 [TBL] [Abstract][Full Text] [Related]
19. MK-801 alters the effects of priming with L-DOPA on dopamine D1 receptor-induced changes in neuropeptide mRNA levels in the rat striatal output neurons. Van De Witte SV; Groenewegen HJ; Voorn P Synapse; 2002 Jan; 43(1):1-11. PubMed ID: 11746728 [TBL] [Abstract][Full Text] [Related]
20. Blockade of globus pallidus adenosine A(2A) receptors displays antiparkinsonian activity in 6-hydroxydopamine-lesioned rats treated with D(1) or D(2) dopamine receptor agonists. Simola N; Fenu S; Baraldi PG; Tabrizi MA; Morelli M Synapse; 2008 May; 62(5):345-51. PubMed ID: 18297692 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]